Evaluation of Ocular Surface and Meibomian Glands in Patients With Scleroderma.

PURPOSE To evaluate the prevalence of dry eye and meibomian gland dysfunction in patients with scleroderma. METHODS A total of 32 patients with scleroderma (study group) and 31 healthy subjects (control group) were enrolled. Besides routine ophthalmologic evaluation, Schirmer 1 test, tear break-up time, tear osmolarity, ocular surface staining with fluorescein (Oxford score), and Ocular Surface Disease Index (OSDI) score, meibomian gland dysfunction evaluation (foamy tears, telangiectasia of the eyelid, eyelid contour abnormalities, and meibomian plugs), and meibography were performed. RESULTS Sixty-four eyes of 32 patients with scleroderma and 62 eyes of 31 healthy individuals were evaluated. Mean ages of the study group was 48.34 ± 9.73 years (21-62 years) and of the control group was 45.84 ± 4.42 years (38-54 years) (P = 0.067). Mean duration of systemic sclerosis or scleroderma in study group was 9.78 ± 7.40 years (1-30 years). Mean tear break-up time was shorter in study group than that in the control group (P < 0.0005). No statistical differences were detected for osmolarity, OSDI score, and Schirmer 1 values between groups (P = 0.051, P = 0.053, and P = 0.358, respectively). The prevalence of grade 1 and higher Oxford score was higher in the study group (P < 0.0005). Upper meiboscores of grade 1 and higher were found to be more common in the study group than those in the control group (P = 0.036). The presence of foamy tears and telangiectasia of the eyelids were significantly higher in the study group (P = 0.002 and P = 0.002, respectively). OSDI score was the only significantly correlated data with disease duration (Spearman ρ coefficient = 0.396, P = 0.001). CONCLUSIONS Evaporative type dry eye is more common in patients with scleroderma than the healthy population.

[1]  P. Szodoray,et al.  A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis , 2019, Ocular immunology and inflammation.

[2]  M. Kaya,et al.  Association between Skin Thickness Measurements with Corneal Biomechanical Properties and Dry Eye Tests in Systemic Sclerosis , 2019, Ocular immunology and inflammation.

[3]  M. Cutolo,et al.  Ocular involvement in systemic sclerosis: A systematic literature review, it's not all scleroderma that meets the eye. , 2019, Seminars in arthritis and rheumatism.

[4]  P. Szodoray,et al.  Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis , 2017, Rheumatology International.

[5]  S. Kaya,et al.  Evaluation of the Anterior Segment Parameters of the Patients with Scleroderma , 2017, Ocular immunology and inflammation.

[6]  Ahmed Alawlaqi,et al.  Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal women: a cross-sectional comparison study , 2016, Menopause.

[7]  T. Frech,et al.  Systemic sclerosis: The need for structured care. , 2016, Best practice & research. Clinical rheumatology.

[8]  S. Akar,et al.  Anterior segment parameters and eyelids in systemic sclerosis , 2016, International Ophthalmology.

[9]  R. Soares,et al.  Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. , 2015, Autoimmunity reviews.

[10]  E. Campos,et al.  Sex-Steroid Imbalance in Females and Dry Eye , 2015, Current eye research.

[11]  M. Mayes,et al.  Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers , 2012, Current opinion in rheumatology.

[12]  M. Santhiago,et al.  Evaluation of dry eye signs and symptoms in patients with systemic sclerosis , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[13]  A. Karatepe,et al.  Evaluation of Cornea and Anterior Chamber with Pentacam in Scleroderma Cases , 2011 .

[14]  M. Santhiago,et al.  Ocular findings in patients with systemic sclerosis , 2011, Clinics.

[15]  Gerd Geerling,et al.  An objective approach to dry eye disease severity. , 2010, Investigative ophthalmology & visual science.

[16]  A. Herrick,et al.  Ocular manifestations of scleroderma. , 2009, Survey of ophthalmology.

[17]  U. Müller-Ladner,et al.  Skin involvement in systemic sclerosis. , 2008, Rheumatology.

[18]  Kenji Inoue,et al.  Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. , 2008, Ophthalmology.

[19]  J. Sibilia,et al.  Incidence and prevalence of systemic sclerosis: a systematic literature review. , 2008, Seminars in arthritis and rheumatism.

[20]  A. Poncelet,et al.  Peripheral neuropathy in scleroderma , 2003, Muscle & nerve.

[21]  J. Buring,et al.  Prevalence of dry eye syndrome among US women. , 2003, American journal of ophthalmology.

[22]  J. Buring,et al.  Hormone replacement therapy and dry eye syndrome. , 2001, JAMA.